MED
Medifast, Inc.12.03
+0.03+0.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
GLP-1 off-ramp boosts productivity
Q&A zeroed in on coach productivity's roots, with Chard attributing the first YoY gain since mid-2022 to retrained coaches pitching metabolic health to GLP-1 off-rampers—two-thirds quit after two years, often regaining weight. Roughly one-quarter of clients have used or are on GLP-1s. New products excite the field by targeting visceral fat cuts and lean mass preservation post-GLP. Nick hinted revenue could stabilize by year-end versus FY2026's $270M-$300M guide. No walk-backs; it burnished prepared green shoots. Productivity must endure. Watch off-ramp traction and coach tenure shift.
Key Stats
Market Cap
132.23MP/E (TTM)
601.50Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
8-K
8-K
Q4 revenue plunges 37%
Medifast reported Q4 2025 revenue of $75.1M, down 36.9% from $119.0M last year, with active earning coaches dropping 40.6% to 16,100 yet revenue per coach up 6.2% to $4,664. Net loss hit $18.1M ($1.65/share), driven by a $12.1M non-cash tax valuation allowance. Balance sheet strong at $167.3M cash, no debt. Guides 2026 revenue $270M-$300M, loss/share $1.55-$2.75 amid GLP-1 pressures.
10-K
FY2025 results
Medifast's FY2025 revenue plunged 36% y/y to $385.8M amid a 40.6% drop in active earning coaches to 16,100 in Q4 from 27,100 y/y, though average revenue per coach rose 6.2% to $4,664 (derived). Q4 coach count fell sequentially from 19,500 in Q3, underscoring persistent client acquisition woes tied to GLP-1 drugs. Gross margins slipped to 71.3% from 73.8% on fixed cost deleverage, flipping operations to a $14.2M loss versus $2.9M profit; net loss hit $18.7M or ($1.70) diluted EPS on a 10.98M share base. Cash swelled to $167.3M with no debt or dividends; $1.3M shares remain authorized for buyback. No 2026 guidance disclosed. GLP-1 competition threatens further coach erosion.
8-K
Leadership transition announced
Medifast's Chief Business Operations Officer Anthony Tyree departs effective December 31, 2025, with a $707K severance lump sum. Nicholas Johnson rises to President on January 5, 2026, poised to succeed CEO Dan Chard, who shifts to non-executive Chairman June 1 amid pay cuts from $1M to $800K salary. Leadership reshuffle signals CEO succession. No disagreements noted.
8-K
Medifast Q3 revenue plunges 36%
Medifast reported Q3 2025 revenue of $89.4 million, down 36.2% from $140.2 million last year, as active earning OPTAVIA coaches fell 35% to 19,500 amid GLP-1 medication pressures. The company swung to a $2.3 million net loss from prior profit, yet holds $173.5 million in cash with no debt. Revenue per coach dipped slightly to $4,585. It eyes Q4 revenue of $65-80 million, betting on metabolic health pivot.
IPO
Website
Employees
Sector
Industry
HLF
Herbalife Ltd.
14.45-0.45
IMTH
Innovative MedTech Inc.
0.08+0.00
LFMD
LifeMD, Inc.
3.42+0.15
MDT
Medtronic plc.
97.72-0.85
MRM
MEDIROM Healthcare Technologies
2.10+0.01
MWAI
MedwellAI, Inc.
0.52+0.00
OPCH
Option Care Health, Inc.
32.93-0.61
SG
Sweetgreen, Inc.
6.91-0.34
WOOF
Petco Health and Wellness Compa
3.05-0.05
WW
WW International, Inc.
27.23+2.94